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Abstract
Registry or national dialysis data show that a sizeable proportion of contemporary dialysis patients 
have substantial levels of residual kidney function especially upon transitioning to dialysis therapy. 
However, among incident hemodialysis patients, the prevailing paradigm has been to initiate “full-
dose” thrice-weekly treatment schedules irrespective of native kidney function in most developed 
countries. Recognizing the benefits of residual kidney function upon the health and survival of 
dialysis patients, there has been growing interest in incremental hemodialysis, in which dialysis 
frequency and dose are tailored according to the degree of patients’ residual kidney function. 
Infrequent hemodialysis can also be used for those who prefer a more conservative approach in 
managing uremia. Clinical practice guidelines support the use of twice-weekly hemodialysis 
among patients with adequate residual kidney function (renal urea clearance >3ml/min/1.73m2), 
and a growing body of evidence indicates that incremental hemodialysis is associated with better 
preservation of residual kidney function without adversely impacting survival. Nonetheless, 
incremental hemodialysis remains an underutilized approach in this population. In this review, we 
will discuss the history of the twice- versus thrice-weekly hemodialysis schedules; current clinical 
practice guidelines regarding infrequent hemodialysis; emerging data on incremental treatment 
regimens and outcomes; and guidelines for the practical implementation of incremental and 
infrequent hemodialysis in the clinical setting.
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INTRODUCTION
Each year, approximately 100,000 patients transition to hemodialysis as a live-saving 
therapy for end-stage renal disease (ESRD) in the United States (US).1 While a considerable 
number of patients may commence hemodialysis with substantial residual kidney function, 
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the current paradigm in the US and most developed countries is to initiate “full-dose” thrice-
weekly treatment schedules. However, an increasing body of evidence suggests that an 
incremental and infrequent hemodialysis schedule, in which dialysis frequency and dose are 
tailored according to degree residual kidney function, may be a more optimal regimen for 
patients initiating treatment with considerable native kidney function.2–11 Those who prefer 
a more conservative hemodialysis treatment approach may also prefer the infrequent 
hemodialysis regimen such as once to twice-weekly dialysis sessions. The objectives of this 
review are to discuss the origins of the twice- versus thrice-weekly hemodialysis schedule; 
current clinical practice guidelines regarding hemodialysis frequency; rationale for 
incremental and infrequent hemodialysis regimens and emerging data on relevant outcomes; 
and recommendations on its implementation in clinical practice.
HISTORY OF THRICE-WEEKLY HEMODIALYSIS
Through a process of trial and error, the thrice-weekly hemodialysis schedule evolved into 
the standard of care for dialysis treatment approximately one-half century ago.10 In 1960, 
the initial maintenance hemodialysis patients received dialysis treatment every five to seven 
days following Dr. Scribner’s innovation of the first permanent vascular access device at the 
University of Washington.12,13 Due to complications of peripheral neuropathy ensuing from 
retained uremic toxins and malignant hypertension resulting from volume overload under 
this once-weekly schedule, hemodialysis frequency was increased to two-times-per-week 
with 12 to 20 hour treatment sessions. However, this 12 to 20 hour twice-weekly schedule 
proved to be taxing to patients, prompting their providers to shift towards six to eight hour 
three-times-per-week overnight hemodialysis schedules based on the experiences of 
colleagues in London who first prescribed overnight dialysis treatment.14
By the time that the United States Congress passed legislation for Medicare’s ESRD 
Program in 1972, with subsequent launching of the program in 1973, the three-times-per-
week schedule was considered to be the optimal regimen in administering hemodialysis.
8,12,13
 Thought to be the best concession for providing adequate dialysis to the greatest 
number of ESRD patients with limited resources, the thrice-weekly hemodialysis schedule 
has remained the prevailing paradigm for past five decades.
ADEQUACY TARGETS: CLINICAL PRACTICE GUIDELINES
While recommendations from the 1997 National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative (KDOQI) Hemodialysis Adequacy Group endorsed dialysis 
initiation at a glomerular filtration rate (GFR) of 10ml/min/1.73m2,15 a more recent 2006 
KDOQI guidelines statement has indicated that dialysis initiation may be indicated at higher 
levels of GFR (<15ml/min/1.73m2) in the setting of symptoms or declining health associated 
with loss of kidney function.16 Consequently, a greater proportion of contemporary dialysis 
patients may be initiating renal replacement therapy with higher levels of residual kidney 
function. Indeed, United States Renal Data System (USRDS) data show that, among patients 
initiating hemodialysis in the United States in 2013, as many as 40% had estimated GFRs 
exceeding 10ml/min/1.73m2.17
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Among patients lacking substantial residual kidney function, defined as a residual urea 
clearance (KRU) of <2ml/min/1.73m2, KDOQI guidelines recommended a single pool Kt/V 
of 1.2 to 1.4 per session as minimally adequate and target dialysis doses, respectively, with a 
minimum treatment time of three hours per session; guidelines advise against a less than 
thrice-weekly hemodialysis schedule in these patients.16 Among patients with substantial 
residual kidney function (KRU of >3ml/min/1.73m2), the 2006 KDOQI guidelines indicated 
that the minimal session single pool Kt/V can be reduced (i.e., dose reduction to 60% of the 
minimum target of those without residual kidney function) and twice-weekly hemodialysis 
would be permissible. Hence, twice-weekly hemodialysis may be advised if KRU exceeds 3 
ml/min/1.73m2, based on the ability to achieve a single pool Kt/V of >1.2 as well as a 
weekly standard Kt/V of >2.2 with a hemodialysis treatment time of four hours, but it should 
not continue once KRU drops below 2 ml/min/1.73m2.16,18 Among patients who are 
prescribed infrequent (less than thrice-weekly) hemodialysis schedules due to substantial 
residual kidney function, the 2006 KDOQI guidelines recommend that KRU be rechecked at 
least quarterly and following any event that may be associated with an abrupt decline in 
residual kidney function.16
RESIDUAL KIDNEY FUNCTION AND RATIONALE FOR THE INCREMENTAL 
DIALYSIS REGIMEN
Despite these guidelines, the current norm in the US until recently has been to initiate 
hemodialysis patients on a full-dose, three-times-per week schedule irrespective of 
underlying kidney function. However, an incremental hemodialysis schedule, in which 
hemodialysis frequency and dose are tailored according to degree residual kidney function, 
may be a preferred means of preserving native kidney function in patients initiating dialysis.
3,4,8,10
 Twice-weekly hemodialysis can also be used for those patients who prefer a more 
conservative management approach regardless of residual kidney function, particularly 
amongst those who would otherwise decline dialysis therapy if it were a thrice-weekly 
regimen. Hence, this approach may serve as a compromise and an alternative to categorical 
decline or withdrawal of dialysis therapy.
It is thought that hemodialysis in and of itself promotes loss of residual kidney function due 
to (1) ischemic insult caused by intra-dialytic hypotension and post-dialysis hypovolemia, 
(2) release of nephrotoxic inflammatory mediators during the hemodialysis procedure, (3) 
reduction in circulating urea leading due a reduction in osmotic diuresis, and (4) deactivation 
of remaining nephrons.19–22 While some data indicate that residual kidney function may be 
better preserved among hemodialysis patients than previously thought (70% and 14 to 20% 
of patients retaining residual kidney function one and three to five years after dialysis 
initiation, respectively23), other studies suggest that hemodialysis patients experience a more 
rapid decline in native kidney function vs. peritoneal dialysis patients.20 Recent data also 
suggest that frequent hemodialysis accelerates residual renal function decline. In a corollary 
study of the Frequent Hemodialysis Network Nocturnal trial, among non-anuric patients, 
patients assigned to frequent hemodialysis (i.e., six-times-per-week) had greater loss of 
residual kidney function, ascertained by urine volume, urea clearance, and creatinine 
clearance, compared to those prescribed conventional (i.e., three-times-per-week) 
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hemodialysis at four and 12 months follow up.24 Furthermore, patients in the frequent 
hemodialysis arm had a lower nadir intradialytic systolic blood pressure vs. the conventional 
group, suggesting that ischemic kidney damage may have been contributory.
Given its continuous nature, residual kidney function offers considerable benefits with 
respect to volume control, solute clearance, and uremic toxin removal even among patients 
receiving dialysis.25 For example, greater native kidney function may reduce the likelihood 
of large interdialytic weight gains, resulting in lower ultrafiltration rates, intradialytic 
hypotension, and myocardial stunning.23,26–28 Lesser interdialytic fluid accumulation may 
also lead to better overall fluid balance and reduced left ventricular hypertrophy as a 
substrate for malignant ventricular arrhythmias and sudden cardiac death.29 In addition, 
residual kidney function provides greater clearance of middle and large molecular weight 
solutes vs. hemodialysis, and thereby may result in better phosphorus control.28,30,31 This 
may in turn allow for more dietary liberalization, leading to improved nutritional status and 
better health-related quality of life.10 Furthermore, substantial residual kidney function may 
be associated with improved anemia parameters and lower erythropoietin-stimulating 
requirements, as well as reduced inflammatory status.32
A mounting body of data has demonstrated the importance of residual kidney function upon 
the survival and health-related quality of life of both peritoneal dialysis and hemodialysis 
patients (Table 1).23,32–38 With respect to patients newly initiating hemodialysis, Shafi et al. 
examined the relationship between residual kidney function, defined as urine output >250ml, 
with clinical outcomes among 734 incident hemodialysis patients across 81 dialysis clinics 
from the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) 
cohort.32 Among patients who had urine output >250ml at baseline (84% of the cohort), 
presence of urine output was not associated with better survival but was linked with better 
health-related quality of life. However, among a subcohort of 579 patients with one-year 
urine output data, those with preservation of urine output >250ml (28% of the cohort) had a 
30% lower all-cause death risk, as well as a trend towards lower cardiovascular mortality.
A subsequent study of 6538 incident hemodialysis patients by Obi et al. from a large US 
dialysis organization examined the association between one-year and annual change in 
residual kidney function (defined by renal urea clearance and urine volume at baseline and 
one year follow up) with survival.34 The investigators found that higher renal urea clearance 
and urine volume one year after hemodialysis initiation was associated with better survival 
independent of case-mix characteristics, ultrafiltration rate, and laboratory data. They also 
observed a gradient association between loss of renal urea clearance, such that those with a 
decline of 6.0 and 3.0ml/min/1.73m2/year had a 2.0-fold and 1.25-fold higher mortality risk, 
respectively, while those who had no change or a rise of 3.0ml/min/1.73m2/year had a 19% 
and 39% lower mortality risk, respectively (reference: renal urea clearance decline of 
1.5ml/min/1.73m2/year). A similar pattern of findings was observed for annual change in 
urine output.
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INCREMENTAL HEMODIALYSIS AND OUTCOMES
This concept of “incremental dialysis” was first described amongst peritoneal dialysis 
patients, in whom residual kidney function has been used as a guide to establish and adjust 
the dialysis prescription.39,40 Using an individualized, patient-centered approach, both native 
kidney function and dialysis clearance are included in the total weekly clearance target, and 
upon loss of residual kidney function the peritoneal dialysis prescription is escalated. 
Similarly, the assessment of hemodialysis adequacy should also incorporate dialysis session 
dialysis dose and duration, frequency of hemodialysis, and amount of residual kidney 
function.41 Indeed, a number of studies have examined the relationship between incremental 
hemodialysis regimens (i.e., once- and twice-weekly dialysis) with relevant clinical 
outcomes such as preservation of residual kidney function and mortality in dialysis patients 
(Table 2).2,5–7,9,11
Residual Kidney Function
In a Taiwanese study of 74 prevalent hemodialysis patients who maintained the same 
treatment schedules over time by Lin et al., the rate of residual kidney function decline 
(defined by creatinine clearance and urine output) was compared among patients prescribed 
twice vs. thrice-weekly therapy with similar baseline creatinine clearance levels and urine 
output.6 After a mean follow up of 18 months, patients receiving twice-weekly hemodialysis 
had a slower rate of residual kidney function decline vs. those receiving thrice-weekly 
hemodialysis. However, it should be noted that this study did not account for differences in 
socio-demographics nor comorbidities between the two groups.
A subsequent study of 85 incident hemodialysis patients in Shanghai by Zhang et al. 
compared the trajectory of residual kidney function defined by urine output amongst patients 
who were initiated and maintained on twice-weekly hemodialysis for six months or longer 
vs. those who were initiated and maintained on thrice-weekly hemodialysis over the entire 
study period.11 At baseline, the proportion of patients with residual kidney function (defined 
as urine output ≥200ml/day) was greater in patients receiving twice-weekly vs. thrice-
weekly hemodialysis. Over the course of one year, the proportion of patients with residual 
kidney function loss (urine volume <200ml/day) was lower, and the time to residual kidney 
function loss was longer among patients initiated on twice vs. thrice-weekly hemodialysis. 
In a subcohort of 48 incident hemodialysis patients (vintage <12 months) whose baseline 
urine output was >500 ml/day, each additional hemodialysis session per week was found to 
be associated with a 7.2-fold higher risk of residual kidney function loss (defined as urine 
output <200ml/day).
Most recently, in a study of 23,645 incident hemodialysis patients from a large US dialysis 
organization, Obi et al. examined the relationship between an incremental hemodialysis 
regimen (defined as greater than six consecutive weeks of twice-weekly hemodialysis in the 
first quarter of dialysis) vs. conventional regimen (defined as thrice-weekly hemodialysis) 
with preservation of residual kidney function (ascertained by KRU and urine volume) over 
the course of one year.9 Roughly half of patients with baseline KRU data who survived the 
first year (N=23,645) had sufficient residual kidney function to qualify for twice-weekly 
hemodialysis, but the overall prescription of this regimen was quite low (<2%) over the 
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study period. Among 351 patients receiving incremental regimens who were matched on the 
basis of baseline KRU, urine volume, age, sex, race, vascular access type, and diabetes to 
8068 patients receiving conventional regimens, those receiving incremental hemodialysis 
showed slower decline in residual kidney function over time in multivariable adjusted 
models. More specifically, patients receiving incremental hemodialysis had a 16% and 15% 
higher KRU and urine volume in the second quarter, and these differences persisted over the 
subsequent quarters.
Mortality
In a study of 15,067 incident and prevalent hemodialysis patients from the US Dialysis 
Morbidity and Mortality Study cohort by Hanson et al., the investigators examined the 
relationship between twice-weekly vs. thrice-weekly hemodialysis and mortality risk among 
patients stratified by dialysis vintage.2 Among prevalent hemodialysis patients, twice-
weekly treatment was associated with lower mortality risk; however, patients in the twice-
weekly group had more favorable patient characteristics, and analyses did not account for 
differences in residual kidney function between the two groups. However, in a separate 
analysis of incident hemodialysis patients that did account for residual kidney function, 
twice-weekly vs. thrice-weekly treatments demonstrated similar mortality risk. In a smaller 
but more contemporary cohort of 1288 hemodialysis from the Shanghai Renal Registry, the 
association between twice-weekly vs. thrice-weekly hemodialysis with mortality was also 
examined according to dialysis vintage.5 In adjusted analyses of the overall cohort, twice-
weekly vs. thrice-weekly hemodialysis showed similar mortality risk. In unadjusted analyses 
that stratified patients according to duration of dialysis, twice-weekly vs. thrice-weekly 
hemodialysis demonstrated longer survival times amongst both incident and prevalent 
(vintage >5 months) patients; however, these data provide limited inference due to non-
consideration of confounders and lack of information on residual kidney function.
Similar to the US Morbidity and Mortality substudy, the aforementioned study by Obi et al. 
examined the relationship between incremental vs. conventional hemodialysis schedules and 
mortality risk. In the overall cohort (351 incremental hemodialysis patients matched to 8068 
conventional hemodialysis patients), there was no difference in mortality risk between the 
two groups.9 However, in subgroup analyses stratified by residual kidney function, 
incremental hemodialysis was associated with a 61% mortality risk among patients with 
“inadequate residual kidney function” (defined as KRU ≤3ml/min/1.73m2 or urine volume 
≤600ml/day). However, in those with “adequate residual kidney function” (defined as KRU 
>3/min/1.73m2 or urine volume >600ml/day), incremental vs. conventional hemodialysis 
were associated with similar mortality risk. Notably, a significant trend towards better 
survival was observed across incrementally higher renal urea clearance levels and 
incrementally lower weekly interdialytic weight gains.
Most recently, Mathew et al. examined mortality risk across a spectrum of hemodialysis 
frequency schedules among a matched cohort of 434, 50,162, and 160 incident hemodialysis 
patients receiving incremental, conventional, and frequent treatments.7 After accounting for 
residual kidney function, patients receiving incremental hemodialysis were found to have a 
similar mortality risk vs. those receiving conventional schedules. However, patients 
Rhee et al. Page 6
Panminerva Med. Author manuscript; available in PMC 2018 June 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
receiving frequent hemodialysis had a 56% higher mortality risk than the incremental group. 
Notably, comorbidity burden was observed to be an important modifier of treatment 
schedule and mortality. Among patients with higher Charlson Comorbidity Scores ≥5, 
incremental hemodialysis was associated with a 77% higher death risk. However, among 
patients with low or moderate comorbidity burden, there was no difference in survival 
among the incremental vs. conventional treatment groups.
PRACTICAL IMPLEMENTATION OF INCREMENTAL DIALYSIS
Given the benefits of residual kidney function upon the health and survival of ESRD 
patients, there is compelling rationale to consider incremental and infrequent hemodialysis 
regimens as a new paradigm for dialysis initiation or conservative dialysis in appropriately-
selected patients. In most of the aforementioned studies, incremental dialysis was associated 
with equivalent to better survival vs. conventional treatments.2,5,7,9 However, it is important 
to note that higher mortality risk was observed among patients with inadequate residual 
kidney function and higher comorbidity burden.7,9
To provide guidance in the optimal implementation of incremental hemodialysis, experts in 
the field have proposed practical criteria that can be used to identify patients who are 
suitable for this regimen (Figure 1).4 In addition to the 2006 KDOQI guideline’s definitions 
of adequate residual kidney function defined by KRU for twice-weekly hemodialysis,16 the 
presence of substantial urine volume (>500ml/day) is an important criteria given the 
potential risk of high interdialytic weight gains and volume overload with less frequent 
hemodialysis regimens.4 In addition to having adequate KRU and urine volume, experts 
have also advised that patients should meet most (i.e., five out of nine) of the following 
criteria to qualify for incremental hemodialysis: (1) Limited fluid retention between two 
consecutive hemodialysis sessions with a fluid gain <2.5kg or <5% of ideal dry weight 
without hemodialysis for three to four days; (2) limited or readily manageable 
cardiovascular or pulmonary symptoms without clinically significant fluid overload; (3) 
suitable body size relative to residual kidney function (i.e., patients of large body habitus 
may be suitable for twice-weekly hemodialysis if not hypercatabolic); (4) infrequent or 
readily manageable hyperkalemia (serum potassium >5.5mEq/l); (5) infrequent or readily 
manageable hyperphosphatemia (serum phosphate >5.5mg/dl); (6) adequate nutritional 
status without hypercatabolism; (7) absence of profound anemia (hemoglobin >8g/dl) and 
appropriate responsiveness to erythropoietin-stimulating agents; (8) infrequent 
hospitalization and easily manageable comorbidities; and (9) good health-related quality of 
life.
It is important to highlight that frequent (i.e., at least quarterly) assessment of residual 
kidney function is a cornerstone of the incremental hemodialysis prescription.4,16,18,42 As 
residual kidney function will inevitably decline over time, patients initiating twice-weekly 
hemodialysis may ultimately need to transition to thrice-weekly or more frequent schedules. 
Hence, patients should receive ample education that at the point that their residual kidney 
function can no longer compensate for a less frequent hemodialysis schedule, their dialysis 
frequency and dose will need to be adjusted accordingly. Given the differential rates of 
native kidney function decline over time, as well as the potential harms of applying 
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incremental hemodialysis to incorrect patient populations (e.g., volume overload leading to 
ventricular hypertrophy, high ultrafiltration rates/myocardial stunning, hyperkalemia, 
cardiovascular disease and death), routine assessment of residual kidney function is 
imperative in identifying the appropriate transition point from a twice-weekly to thrice-
weekly schedule for each patient.
CONCLUSIONS
While a growing body of evidence suggests that incremental and infrequent hemodialysis 
regimens are associated with better preservation of residual kidney function without 
adversely impacting survival, further research is needed in multiple areas to define its 
optimal implementation on a broad scale. Rigorous studies are needed to examine how 
infrequent hemodialysis influences other relevant endpoints, including patient-centered 
outcomes such as health-related quality of life, mental health, physical function, and 
cognition, as well as cost-effectiveness.10 Given the challenges of routinely measuring 24-
hour urine urea and creatinine clearances and urine output, future research is needed to 
identify innovative, straightforward, and accurate methods of residual kidney function 
assessment in the clinical setting.18,42 Considerable study is also needed to determine the 
optimal patient phenotype for incremental hemodialysis, as well as more precisely defining 
the appropriate transition points from twice-weekly to more frequent hemodialysis 
schedules.
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Figure 1. Proposed criteria for implementation of incremental hemodialysis.4,16
Abbreviations: IDWG, interdialytic weight gain; HD, hemodialysis; RKF, residual kidney 
function.
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